2019 Fiscal Year Final Research Report
Analysis of host cell entry of Crimean-Congo hemorrhagic fever virus and identification of the therapeutic targets
| Project/Area Number |
19K21260
|
|---|
| Project/Area Number (Other) |
18H06146 (2018)
|
|---|
| Research Category |
Grant-in-Aid for Research Activity Start-up
|
| Allocation Type | Multi-year Fund (2019)
Single-year Grants (2018) |
|---|
| Review Section |
0803:Pathology, infection/immunology, and related fields
|
|---|
| Research Institution | Nagasaki University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2018-08-24 – 2020-03-31
|
| Keywords | クリミア・コンゴ出血熱ウイルス / 細胞侵入過程 / シュードウイルス / 侵入阻害剤 / スクリーニング |
|---|
| Outline of Final Research Achievements |
Crimean-Congo hemorrhagic fever virus (CCHFV) causes a severe infectious disease in human. Although it affects a wide geographic region including Africa, the Middle East, Eastern Europe and central Asia, currently there is no approved vaccine and therapeutics. Moreover, the replication competent virus needs to be used in the Biosafety Level 4 (BSL4) laboratory, making the research difficult to conduct.
In this study, we developed efficient methods to produce pseudotyped virus bearing glycoproteins of CCHFV and the closely-related Hazara virus. With a high-throughput assay using the pseudotyped viruses, which can be performed in the BSL2 laboratory, 1280 compounds were screened for the antiviral activities, resulting in identification of CCHFV entry inhibitors.
This newly developed assay can be an effective tool for the therapeutic development as well as the basic virological research of CCHFV.
|
| Free Research Field |
ウイルス学
|
| Academic Significance and Societal Importance of the Research Achievements |
野生型CCHFVはバイオセーフティーレベル4（BSL4）施設にて扱う必要があり、限られた研究者が限られた手法でしか研究出来ない。本研究で開発したシュードウイルスによる実験系を用いれば、細胞侵入過程に限定されるが、BSL2施設にて効率的にウイルス学的解析や治療法の探索が可能となる。更に、患者や回復者血清の中和抗体価の安全な評価にも活用出来る。従って本研究成果は、クリミア・コンゴ出血熱の病態解析、治療法開発、疫学調査など様々な研究に寄与するものと考えられる。
|
